Hiam Chemaitelly

List of Publications by Year in Descending Order

143 papers	3,528 citations	31 h-index	54 g-index
163 ext. papers	6,460 ext. citations	11.7 avg, IF	6.52 L-index

#	Paper	IF	Citations
143	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.. *Nature Communications*, **2022**, 13, 532	17.4	13
142	Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar.. *New England Journal of Medicine*, **2022**,	59.2	9
141	Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar.. *New England Journal of Medicine*, **2022**,	59.2	18
140	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2.. *PLoS ONE*, **2022**, 17, e0262897	3.7	0
139	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.. *New England Journal of Medicine*, **2022**,	59.2	52
138	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience.. *Journal of Global Health*, **2022**, 12, 05004	4.3	0
137	Hepatitis C virus among blood donors and general population in Middle East and North Africa: Meta-analyses and meta-regressions. *World Journal of Meta-analysis*, **2022**, 10, 12-24	0.5	0
136	Waning effectiveness of COVID-19 vaccines.. *Lancet, The*, **2022**, 399, 771-773	40	8
135	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.. *New England Journal of Medicine*, **2022**,	59.2	36
134	First characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017-2020.. *PLoS ONE*, **2022**, 17, e0264737	3.7	0
133	COVID-19 Disease Severity in Children Infected with the Omicron Variant.. *Clinical Infectious Diseases*, **2022**,	11.6	11
132	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission.. *Epidemics*, **2022**, 39, 100567	5.1	
131	Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics.. *BMC Infectious Diseases*, **2022**, 22, 458	4	0
130	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. *Nature Communications*, **2022**, 13,	17.4	12
129	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. *Clinical Infectious Diseases*, **2021**, 73, e1830-e1840	11.6	99
128	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar.. *JAMA Internal Medicine*, **2021**,	11.5	15
127	Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant.. *New England Journal of Medicine*, **2021**, 385, 2585-2586	59.2	24

126	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study.. *PLoS Medicine*, **2021**, 18, e1003879	11.6	19
125	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nature Medicine*, **2021**,	50.5	104
124	Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. *New England Journal of Medicine*, **2021**,	59.2	27
123	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. *Global Epidemiology*, **2021**, 3, 100068	2.3	5
122	Severity, criticality, and fatality of the SARS-CoV-2 Beta variant. *Clinical Infectious Diseases*, **2021**,	11.6	8
121	SARS-CoV-2 infection rates in arriving air Travelers in Qatar. *Journal of Travel Medicine*, **2021**,	12.9	1
120	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. *Journal of Clinical Investigation*, **2021**, 131,	15.9	13
119	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *New England Journal of Medicine*, **2021**, 385, e83	59.2	226
118	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1930-1939	27.4	45
117	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Scientific Reports*, **2021**, 11, 6233	4.9	57
116	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. *BMJ Innovations*, **2021**, 7, 327-336	1.8	15
115	Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China. *Vaccines*, **2021**, 9,	5.3	9
114	Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050. *Open Forum Infectious Diseases*, **2021**, 8, ofab218	1	2
113	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. *Open Forum Infectious Diseases*, **2021**, 8, ofab221	1	23
112	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. *Emerging Infectious Diseases*, **2021**, 27, 1343-1352	10.2	38
111	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. *Journal of Travel Medicine*, **2021**, 28,	12.9	33
110	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. *EClinicalMedicine*, **2021**, 35, 100861	11.3	77
109	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. *IScience*, **2021**, 24, 102646	6.1	39

108	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. *Scientific Reports*, **2021**, 11, 11837	4.9	7
107	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nature Medicine*, **2021**, 27, 1614-1621	50.5	144
106	Global epidemiology of in infertile populations: systematic review, meta-analysis and metaregression. *Sexually Transmitted Infections*, **2021**, 97, 157-169	2.8	5
105	Diagnosing type 2 diabetes using Hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. *Acta Diabetologica*, **2021**, 58, 279-300	3.9	4
104	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. *Journal of Global Health*, **2021**, 11, 05005	4.3	40
103	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. *Infection, Genetics and Evolution*, **2021**, 88, 104684	4.5	10
102	Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. *JAMA - Journal of the American Medical Association*, **2021**, 326, 185-188	27.4	27
101	Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine*, **2021**, 385, 187-189	59.2	508
100	Development, translation, and validation of a bilingual questionnaire on unused medications in homes. *Saudi Pharmaceutical Journal*, **2021**, 29, 648-655	4.4	0
99	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. *International Journal of Infectious Diseases*, **2021**, 112, 52-54	10.5	25
98	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. *Scientific Reports*, **2021**, 11, 18182	4.9	22
97	Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. *International Journal of Infectious Diseases*, **2021**, 110, 353-358	10.5	31
96	Hepatitis C Virus in the Middle East and North Africa **2021**, 3027-3052		
95	The HIV Epidemic in the Middle East and North Africa: Key Lessons **2021**, 3053-3079		
94	Characterizing key attributes of COVID-19 transmission dynamics in China's original outbreak: Model-based estimations. *Global Epidemiology*, **2020**, 2, 100042	2.3	17
93	Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt. *International Journal of Epidemiology*, **2020**, 49, 798-809	7.8	7
92	The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. *Addiction*, **2020**, 115, 1244-1262	4.6	8
91	Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. *Hepatology Communications*, **2020**, 4, 577-587	6	2

90	The HIV Epidemic in the Middle East and North Africa: Key Lessons **2020**, 1-27		1
89	Key associations for hepatitis C virus genotypes in the Middle East and North Africa. *Journal of Medical Virology*, **2020**, 92, 386-393	19.7	6
88	Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. *Vaccines*, **2020**, 8,	5.3	6
87	HSV-2 as a biomarker of HIV epidemic potential in female sex workers: meta-analysis, global epidemiology and implications. *Scientific Reports*, **2020**, 10, 19293	4.9	0
86	Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. *Vaccines*, **2020**, 8,	5.3	51
85	Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide. *PLoS ONE*, **2020**, 15, e0237959	3.7	24
84	Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. *PLoS ONE*, **2019**, 14, e0214151	3.7	26
83	Global epidemiology of in infertile populations: protocol for a systematic review. *BMJ Open*, **2019**, 9, e025808	3	4
82	Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. *BMC Medicine*, **2019**, 17, 57	11.4	41
81	Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests. *Hepatology Communications*, **2019**, 3, 325-339	6	15
80	Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Research Synthesis Methods*, **2019**, 10, 476-483	7.2	154
79	Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. *Scientific Reports*, **2019**, 9, 1136	4.9	22
78	The Epidemiology of Herpes Simplex Virus Type 1 in Asia: Systematic Review, Meta-analyses, and Meta-regressions. *Clinical Infectious Diseases*, **2019**, 68, 757-772	11.6	37
77	Epidemiology of Chlamydia trachomatis in the Middle East and north Africa: a systematic review, meta-analysis, and meta-regression. *The Lancet Global Health*, **2019**, 7, e1197-e1225	13.6	16
76	Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. *Journal of Infection*, **2019**, 79, 289-299	18.9	13
75	Epidemiology of , , , , and herpes simplex virus type 2 among female sex workers in the Middle East and North Africa: systematic review and meta-analytics. *Journal of Global Health*, **2019**, 9, 020408	4.3	5
74	HIV epidemiology among female sex workers and their clients in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. *BMC Medicine*, **2019**, 17, 119	11.4	20
73	Hepatitis C Virus in the Middle East and North Africa **2019**, 1-27		2

72	Does infection with induce long-lasting partial immunity? Insights from mathematical modelling. *Sexually Transmitted Infections*, **2019**, 95, 115-121	2.8	12
71	Reply to Brijwal et al. *Clinical Infectious Diseases*, **2019**, 68, 1784	11.6	
70	Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. *Annals of Epidemiology*, **2018**, 28, 452-461	6.4	15
69	Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. *Scientific Reports*, **2018**, 8, 1661	4.9	83
68	Mapping of new HIV infections in Morocco and impact of select interventions. *International Journal of Infectious Diseases*, **2018**, 68, 4-12	10.5	15
67	Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. *Journal of Medical Virology*, **2018**, 90, 131-141	19.7	37
66	Estimating the annual risk of HIV transmission within HIV sero-discordant couples in sub-Saharan Africa. *International Journal of Infectious Diseases*, **2018**, 66, 131-134	10.5	4
65	Temporal evolution of HIV sero-discordancy patterns among stable couples in sub-Saharan Africa. *PLoS ONE*, **2018**, 13, e0196613	3.7	
64	Hepatitis C virus infection spontaneous clearance: Has it been underestimated?. *International Journal of Infectious Diseases*, **2018**, 75, 60-66	10.5	15
63	Self-rated health disparities among disadvantaged older adults in ethnically diverse urban neighborhoods in a Middle Eastern country. *Ethnicity and Health*, **2017**, 22, 490-509	2.2	6
62	Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. *Epidemiology and Infection*, **2017**, 145, 3243-3263	4.3	17
61	Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions. *PLoS ONE*, **2017**, 12, e0187177	3.7	24
60	Characterizing HIV epidemiology in stable couples in Cambodia, the Dominican Republic, Haiti, and India. *Epidemiology and Infection*, **2016**, 144, 90-6	4.3	4
59	P10.15 The epidemiology of hepatitis c virus in afghanistan: a systematic review and meta-analysis. *Sexually Transmitted Infections*, **2015**, 91, A170.2-A171	2.8	
58	The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. *International Journal of Infectious Diseases*, **2015**, 40, 54-63	10.5	29
57	The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. *PLoS ONE*, **2015**, 10, e0135281	3.7	42
56	Dynamics of non-cohabiting sex partnering in sub-Saharan Africa: a modelling study with implications for HIV transmission. *Sexually Transmitted Infections*, **2015**, 91, 451-7	2.8	17
55	The risk of HIV transmission within HIV-1 sero-discordant couples appears to vary across sub-Saharan Africa. *Epidemics*, **2014**, 6, 1-9	5.1	34

54	Prevention of type II diabetes mellitus in Qatar: Who is at risk?. *Qatar Medical Journal*, **2014**, 2014, 70-81	0.5	13
53	Sources of HIV incidence among stable couples in sub-Saharan Africa. *Journal of the International AIDS Society*, **2014**, 17, 18765	5.4	51
52	Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. *Systematic Reviews*, **2014**, 3, 146	3	23
51	The role of gender in the association of social capital, social support, and economic security with self-rated health among older adults in deprived communities in Beirut. *Quality of Life Research*, **2013**, 22, 1371-9	3.7	37
50	External infections contribute minimally to HIV incidence among HIV sero-discordant couples in sub-Saharan Africa. *Sexually Transmitted Infections*, **2013**, 89, 138-41	2.8	19
49	Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. *Aids*, **2013**, 27, 251-60	3.5	31
48	Prevention during the epidemiologic shift to chronic illness: a case control study of risk factors associated with cardiovascular disease in Qatar **2013**, 2013,		3
47	An apparent lack of epidemiologic association between hepatitis C virus knowledge and the prevalence of hepatitis C infection in a national survey in Egypt. *PLoS ONE*, **2013**, 8, e69803	3.7	18
46	Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. *Sexually Transmitted Infections*, **2012**, 88, 51-7	2.8	68
45	The importance of diabetes mellitus in the global epidemic of cardiovascular disease: the case of the state of Qatar. *Transactions of the American Clinical and Climatological Association*, **2012**, 123, 193-207; discussion 207-8	0.9	6
44	Developing capacities in aging studies in the Middle East: Implementation of an Arabic version of the CANE IV among community-dwelling older adults in Lebanon. *Aging and Mental Health*, **2011**, 15, 605-17	3.5	10
43	Work and mental health: the case of older men living in underprivileged communities in Lebanon. *Ageing and Society*, **2010**, 30, 25-40	1.7	9
42	Validation of the Arabic version of the short Geriatric Depression Scale (GDS-15). *International Psychogeriatrics*, **2008**, 20, 571-81	3.4	43
41	Effect of narghile and cigarette smoking on newborn birthweight. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2008**, 115, 91-7	3.7	45
40	Argileh smoking among university students: a new tobacco epidemic. *Nicotine and Tobacco Research*, **2004**, 6, 457-63	4.9	67
39	Knowledge, attitudes, and practices of argileh (water pipe or hubble-bubble) and cigarette smoking among pregnant women in Lebanon. *Addictive Behaviors*, **2004**, 29, 1821-31	4.2	57
38	Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant		8
37	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar		3

36	Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar		6
35	Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar		2
34	Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar		2
33	Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design		4
32	Can the COVID-19 pandemic still be suppressed? Putting essential pieces together. *Journal of Global Health Reports*,	1.1	2
31	Characterizing the effective reproduction number during the COVID-19 epidemic: Insights from Qatar experience		1
30	Characterizing key attributes of the epidemiology of COVID-19 in China: Model-based estimations		11
29	Age could be driving variable SARS-CoV-2 epidemic trajectories worldwide		6
28	Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses		17
27	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic		21
26	Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting		36
25	Analyzing inherent biases in SARS-CoV-2 PCR and serological epidemiologic metrics		3
24	Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study		10
23	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19		8
22	Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar		12
21	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates		12
20	Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting		5
19	COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar		3

18	Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections		5
17	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates		1
16	Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: Mathematical modeling analyses		4
15	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals		8
14	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2		1
13	Inclusion of cycle threshold (CT) values when reporting SARS-CoV-2 RT-PCR results improves clinical Interpretation in suspected and confirmed COVID-19		1
12	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar		7
11	Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection		9
10	Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar		22
9	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar		32
8	Severity, criticality, and fatality of the SARS-CoV-2 Beta variant		2
7	SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients		2
6	SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks		20
5	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage		6
4	Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections		3
3	Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar		2
2	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar		5
1	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *New England Journal of Medicine*,	59.2	24